Tracers / [225Ac]Ac-SibuDAB
[225Ac]Ac-SibuDAB
Also written as [Ac-225]Ac-SibuDAB
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- investigational
- Syntheses indexed
- 0
What it is
- Compound class
- albumin-binding PSMA-targeted radioligand ((S)-ibuprofen-diaminobutyric acid-PSMA)
- Target / mechanism
- Prostate-specific membrane antigen (PSMA) PMID 40473466
- Clinical application
- Prostate cancer patients, heavily pretreated including prior 177Lu-PSMA therapy PMID 40473466
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
No synthesis has been parsed for this agent yet.
Need this precursor?We can point you to suppliers for [225Ac]Ac-SibuDAB, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.